


What is claimed is:

1. A compound of formula (I)



including salts, solvates, and pharmaceutically functional derivatives thereof, wherein t is 0, 1, 2, 3, or 4;

R^1 is alkyl, alkoxy, halogen, haloalkyl, nitro, cyano, or $-NR^7R^8$, where each of R^7 and R^8 independently are H or alkyl;

A is $-OH$ or $-NR^2R^3$;

each of R^2 and R^3 independently is H or $-(Q^1)_nR^4$;

n is 0, 1 or 2;

Q^1 is alkylene;

each R^4 independently is alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxy, alkoxy, or aryloxy;

X^1 is $-NH-$;

X^2 is $-C(R^5)_2-$;

each R^5 independently is H or alkyl;

Y is aryl or heteroaryl;

Z is $-(Q^2)_mR^6$;

m is 0 or 1;

Q^2 is $-NR^5-$, $-O-$, $-S-$, $-O(CH_2)_p-$, or $-CH_2-$;

p is 1, 2, or 3; and

R^6 is aryl or heteroaryl.

2. The compound of claim 1 wherein X^2 is $-CH_2-$.
3. The compound of claim 2 wherein X^1 is substituted *para* to the depicted cyclopropyl ring.
4. The compound of claim 1 wherein t is 0.
5. The compound of claim 1 wherein Y is aryl.
6. The compound of claim 5 wherein Y is phenyl.

7. The compound of claim 6 wherein said phenyl is unsubstituted or is optionally substituted with C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, or C₁-C₆ haloalkyl.
8. The compound of claim 1 wherein Y is heteroaryl
9. The compound of claim 8 wherein Y is thiazolyl.
10. The compound of claim 9 wherein said thiazolyl is unsubstituted or is optionally substituted with C₁-C₆ alkyl, aryl, or heteroaryl.
11. The compound of claim 1 wherein A is -OH.
12. The compound of claim 11 wherein the compound of formula (I) is a pharmaceutically functional derivative.
13. The compound of claim 12 wherein A is -OR⁹ where R⁹ is alkyl or aryl.
14. The compound of claim 1 wherein Q¹ is unsubstituted alkylene.
15. The compound of claim 1 wherein Q¹ is optionally substituted alkylene.
16. The compound of claim 1 wherein Z is -O-R⁶.
17. The compound of claim 16 wherein R⁶ is phenyl.
18. The compound of claim 17 wherein said phenyl is unsubstituted or is optionally substituted with halogen, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.
19. The compound of claim 1 wherein Z is -R⁶.
20. The compound of claim 19 wherein R⁶ is phenyl.
21. The compound of claim 20 wherein said phenyl is unsubstituted or is optionally substituted with halogen, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.
22. The compound of claim 21 wherein R⁶ is heteroaryl.
23. The compound of claim 1 wherein A is -OH, t is 0, X¹ is -NH-, X² is -CH₂-, Y is phenyl, m is 1, Q² is -O-, and R⁶ is phenyl.
24. The compound of claim 1 wherein A is -OH, t is 0, X¹ is -NH-, X² is -CH₂-, Y is thiazolyl, m is 0, and R⁶ is phenyl substituted with -CF₃.
25. The compound of claim 1 wherein the compound is selected from:
Racemic-(trans)-2-[4-({[3-(phenyloxy)phenyl]methyl}ammonium)phenyl]
cyclopropanecarboxylic acid;
Racemic-(trans)-2-[4-[(4-biphenyl)methyl]amino]phenyl]cyclopropanecarboxylic
acid;
Racemic-(trans)-2-[4-({[4-(2-pyridinyl)phenyl]methyl}amino)phenyl]
cyclopropanecarboxylic acid;
Racemic-(trans)-2-[4-({[3-[(3,4-dichlorophenyl)oxy]phenyl]methyl}ammonium)
phenyl]-cyclopropanecarboxylic acid;

Racemic-(trans)-2-(4-(((3-([4-(methyloxy)phenyl]oxy)phenyl)methyl)ammonium}phenyl)-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(3-[(4-chlorophenyl)oxy]phenyl)methyl]ammonium}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-(4-(((3-([4-(1,1-dimethylethyl)phenyl]oxy)phenyl)methyl)ammonium}phenyl)-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(3-[(3,5-dichlorophenyl)oxy]phenyl)methyl]ammonium}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-(4-(((3-[(trifluoromethyl)phenyl]oxy)phenyl)methyl)ammonium}phenyl)-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(3-[(4-methylphenyl)oxy]phenyl)methyl]ammonium}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(3-[(phenylmethyl)oxy]phenyl)methyl]ammonium}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[4-methyl-2-(phenyloxy)-1,3-thiazol-5-yl]methyl}ammonium)-phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(4-isopropyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[5-(4-chlorophenyl)-2-furanyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(4-[(phenylmethyl)oxy]phenyl)methyl]amino}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(2-[(3,4-difluorophenyl)oxy]-4-methyl-1,3-thiazol-5-yl)methyl]amino}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(5-[4-(trifluoromethyl)phenyl]-2-furanyl)methyl]amino}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(5-[4-(trifluoromethyl)phenyl]-2-thienyl)methyl]amino}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(4-[4-(trifluoromethyl)phenyl]-2-furanyl)methyl]amino}phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[3-(phenylmethyl)phenyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[[3-[(4-nitrophenyl)oxy]phenyl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
Racemic-(trans)-2-{4-[[3-(phenylthio)phenyl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
Racemic-(trans)-2-{4-[[3-[(4-aminophenyl)oxy]phenyl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
(-)-(Trans)-2-{4-[[3-(phenyloxy)phenyl]methyl]amino]phenyl}cyclopropane carboxylic acid;
(+)-(Trans)-2-{4-[(3-phenoxybenzyl)amino]phenyl}cyclopropanecarboxylic acid;
(+)-(Trans)-2-{4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
Enantiomerically enriched (trans)-ethyl-2-{4-[[3-[(3,4-dichlorophenyl)oxy]phenyl]methyl]amino]phenyl}-cyclopropanecarboxylate;
(+)-(Trans)-2-{4-[[3-[(3,4-dichlorophenyl)oxy]phenyl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
(-)-(cis)-2-{4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
Enantiomerically enriched-(trans)-ethyl-2-[2-chloro-4-[[3-(phenyloxy)phenyl]methyl]amino]phenyl}cyclopropanecarboxylate;
(+)-(Trans)-2-[2-chloro-4-[[3-(phenyloxy)phenyl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
Enantiomerically enriched-(trans)-ethyl-2-[2,5-difluoro-4-[[3-(phenyloxy)phenyl]methyl]amino]phenyl}cyclopropanecarboxylate;
(+)-(trans)-2-[2,5-difluoro-4-[[3-(phenyloxy)phenyl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
(+)-(trans)-2-{4-[[3-[(3,5-dichlorophenyl)oxy]phenyl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
(+)-(trans)-2-{4-[[3-[(3-(trifluoromethyl)phenyl)oxy]phenyl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
(+)-(trans)-2-{4-[[3-[(4-methylphenyl)oxy]phenyl]methyl]amino]phenyl}cyclopropanecarboxylic acid;
Racemic-(trans)-2-{4-[(4-biphenylmethyl)amino]phenyl}cyclopropanecarboxamide;
Racemic-(trans)-2-{4-[[4-(2-pyridinyl)phenyl]methyl]amino]phenyl}cyclopropanecarboxamide;

Racemic-(trans)-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}-N-(4-pyridinylmethyl)cyclopropanecarboxamide;
Enantiomerically enriched (trans)-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}-N-(4-pyridinylmethyl) cyclopropanecarboxamide;
Enantiomerically enriched (trans)-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxamide;
Enantiomerically enriched (trans)-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}-N-[(1S)-1-phenylethyl]cyclopropanecarboxamide;
Enantiomerically enriched (trans)-N-hydroxy-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxamide;
Enantiomerically enriched (trans)-N-cyclobutyl-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxamide;
Racemic-(trans)-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxamide;
(+)-(trans)-N-(1-methylethyl)-2-{4-[[{3-(phenyloxy)phenyl)methyl]amino]phenyl}cyclopropanecarboxamide;
Racemic-(trans)-N-isopropyl-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxamide;

Racemic-(trans)-N,N-dimethyl-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxamide;
Racemic-(trans)-2-[4-[[{3-(phenyloxy)phenyl)methyl]amino]phenyl]-N-(4-pyridinylmethyl)cyclopropanecarboxamide;
Racemic-(trans)-N-(4-methoxybenzyl)-2-{4-[[{3-phenoxybenzyl]amino]phenyl}cyclopropanecarboxamide;
Racemic-(trans)-2-{4-[[{3-phenoxybenzyl]amino]phenyl}-N-[4-(trifluoromethyl)benzyl]cyclopropanecarboxamide;
Racemic-(trans)-N-(2-morpholin-4-ylethyl)-2-{4-[[{3-phenoxybenzyl]amino]phenyl}cyclopropanecarboxamide;
Racemic-(trans)-2-{4-[[{3-phenoxybenzyl]amino]phenyl}-N-(2,2,2-trifluoroethyl)cyclopropanecarboxamide;
Racemic-(trans)-N-isopropyl-2-{4-[[{4-isopropyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxamide;

Enantiomerically enriched *N*-isopropyl-2-{4-[[{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl} cyclopropanecarboxamide; and


Enantiomerically enriched *N*-(cyclopropylmethyl)-2-{4-[(3-phenoxybenzyl)amino]phenyl}cyclopropanecarboxamide, including salts, solvates, and physiologically functional derivatives thereof.

26. The compound of claims 1 to 25 substantially as hereinbefore defined with reference to any one of the Examples.
27. A pharmaceutical composition comprising a compound according to claims 1 to 25, and a pharmaceutically acceptable carrier.
28. A compound according to claims 1 to 25 for use as an active therapeutic substance.
29. A compound according to claims 1 to 25 for use in the treatment or prophylaxis of conditions or disorders affected by GPR40.
30. The compound of claim 29 wherein the condition or disorder is one or more of diabetes, obesity, glucose intolerance, insulin resistance, metabolic syndrome X, hyperlipidemia, hypercholesterolemia, atherosclerosis, neurodegenerative diseases, and cerebrovascular conditions.
31. Use of a compound according to claims 1 to 25 in the manufacture of a medicament for use in the treatment or prophylaxis of conditions or disorders affected by GPR40.
32. The use as in claim 31 wherein the condition or disorder is one or more of diabetes, obesity, glucose intolerance, insulin resistance, metabolic syndrome X, hyperlipidemia, hypercholesterolemia, atherosclerosis, neurodegenerative diseases, and cerebrovascular conditions.
33. A method for the treatment or prophylaxis of conditions or disorders affected by GPR40 comprising the administration of a compound according to any one of claims 1 to 25.
34. The method of claim 33 wherein the condition or disorder is one or more of diabetes, obesity, glucose intolerance, insulin resistance, metabolic syndrome X, hyperlipidemia, hypercholesterolemia, atherosclerosis, neurodegenerative diseases, and cerebrovascular conditions.
35. A process for the preparation of enantiomerically enriched-(trans)-ethyl-2-(4-amino-aryl)-cyclopropanecarboxylates comprising:
mixing a nitrobenzene compound, a palladium compound, and a tin compound in an appropriate solvent with heating to prepare a styrene product;

dissolving said styrene product in an appropriate solvent and adding a mixture of a copper (I) trifluoromethanesulfonate-toluene complex and (2R)-4-tert-Butyl-2-{1-[(4R)-4-tert-butyl-4,5-dihydro-1,3-oxazol-2-yl]-1-methylethyl}-4,5-dihydro-1,3-oxazole and ethyldiazoacetate; and


purifying to give enantiomerically enriched cyclopropanecarboxylates.

36. An intermediate of formula IIIId



formula IIIId.

37. An intermediate of formula IIIe



formula IIIe.